Edition:
United Kingdom

Molecular Medicine SpA (MLMD.MI)

MLMD.MI on Milan Stock Exchange

0.50EUR
23 May 2018
Change (% chg)

€-0.01 (-1.77%)
Prev Close
€0.51
Open
€0.51
Day's High
€0.51
Day's Low
€0.50
Volume
1,832,022
Avg. Vol
4,087,141
52-wk High
€0.60
52-wk Low
€0.40

Latest Key Developments (Source: Significant Developments)

MolMed Q1 Net Loss Narrows to EUR 1.2 Mln
Friday, 11 May 2018 

May 14 (Reuters) - MolMed ::REPORTED ON FRIDAY Q1 NET LOSS OF EUR 1.2 MLN VS LOSS EUR 3.7 MLN YEAR AGO.Q1 OPERATING REVENUE OF EUR 5.8 MLN VS EUR 4.4 MLN YEAR AGO.  Full Article

MolMed Starts Collaboration With Orchard Therapeutics For Rare Diseases
Thursday, 12 Apr 2018 

April 12 (Reuters) - Molecular Medicine SpA ::STARTS COLLABORATION WITH ORCHARD THERAPEUTICS ON GENE THERAPY FOR RARE DISEASES.  Full Article

Molmed FY Net Loss Shrinks To EUR 8.5 Mln
Friday, 9 Mar 2018 

March 12 (Reuters) - MOLMED SPA ::REPORTED ON FRIDAY FY TOTAL OPERATING REVENUES EUR 24.0 MLN VS EUR 22.8 MLN YEAR AGO.FY NET LOSS EUR 8.5 MLN VS LOSS EUR 13.9 MLN YEAR AGO.  Full Article

MolMed: Zalmoxis Can Be Reimbursed In Germany For EUR 163,900 Per Infusion
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - MOLECULAR MEDICINE SPA ::SAYS THAT AS OF JAN 15 ZALMOXIS CAN BE PRESCRIBED AND REIMBURSED IN GERMANY AT THE PRICE OF EUR 163,900 PER INFUSION.APPROVED DOSAGE FORESEES ONE OR MORE INFUSIONS, UP TO A MAXIMUM OF FOUR, TILL IMMUNE-RECONSTITUTION IS ACHIEVED.MOLMED WILL BE RESPONSIBLE FOR THE PRODUCTION AND SUPPLY OF ZALMOXIS, WHILE DOMPÉ FARMACEUTICI WILL CONDUCT ACTIVITIES AIMED AT MARKETING THE THERAPY IN GERMANY.DOMPÉ WILL PAY MOLMED A PURCHASE PRICE PROPORTIONAL TO THE REIMBURSED PRICE OF THE PRODUCT.  Full Article

Molmed Q3 net loss narrows to EUR 1.6‍​ mln
Monday, 6 Nov 2017 

Nov 6 (Reuters) - MOLECULAR MEDICINE SPA ::Q3 OPERATING REVENUE EUR ‍​6.2 MILLION VERSUS EUR 3.7 MILLION YEAR AGO.Q3 NET LOSS EUR 1.6‍​ MILLION VERSUS LOSS EUR 5.9 MILLION YEAR AGO.  Full Article

MolMed announces review of strategic agreement with GlaxoSmithKline
Thursday, 1 Sep 2016 

MolMed SpA : Announces amendment of strategic agreement signed with GlaxoSmithKline (GSK) on March 19, 2015 . Agreement relates to MolMed's supply of services for the clinical application of gene therapies based on viral vector cellular transduction until March 31, 2020 . To be eligible, through the 5 year-period covered by the contract, for minimum anticipated revenues of 48 million euros ($53.73 million) from prior 34 million euros .Of minimum anticipated revenues of 48 million euros, around 14 million euros have already been received.  Full Article

Molmed H1 net loss narrows to EUR 8.4 mln
Monday, 1 Aug 2016 

Molmed Spa : H1 total revenue 10.2 million euros ($11.39 million) versus 7.2 million euros a year ago .H1 net loss 8.4 million euros versus loss 11.2 million euros a year ago.  Full Article

Oxford BioMedica grants to MolMed non-exclusive licence under its LentiVector platform technology
Tuesday, 7 Jun 2016 

Molmed Spa : Signs with Oxford BioMedica new non-exclusive licence agreement concerning lentiviral vector technology . Oxford BioMedica grants to Molmed non-exclusive licence under its LentiVector platform technology for manufacturing and development services . At the same time, the parties terminated the agreement dated 10 December 2004 under which Oxford BioMedica granted MolMed a world-wide, exclusive licence on development and commercialisation of certain products in the field of genetically modified T lymphocytes transduced with retroviral vectors used in research and ex vivo gene therapy, including Zalmoxis .As a result of this agreement settlement, MolMed owes no outstanding royalties to Oxford BioMedica while keep using the above mentioned technology, in the ongoing development and potential commercialization of Zalmoxis.  Full Article

BRIEF-MolMed Q1 Net Loss Narrows to EUR 1.2 Mln

* REPORTED ON FRIDAY Q1 NET LOSS OF EUR 1.2 MLN VS LOSS EUR 3.7 MLN YEAR AGO